AB0397 EPIDEMIOLOGY AND CLINICAL FEATURES OF OPHTHALMOLOGICAL MANIFESTATIONS IN BEHÇET’S DISEASE. STUDY OF 50 PATIENTS OF A SERIES OF 120 PATIENTS IN A REGION IN NORTHERN SPAIN
Authors: A. Herrero-Morant, G. Suárez-Amorín, R. Demetrio-Pablo, L. Sanchez-Bilbao, C. Álvarez-Reguera, D. Martínez-López, R. Fernández Ramón, J. L. Martín-Varillas, M. C. Mata-Arnaiz, M. Á. González-Gay, R. Blanco
Journal: Annals of the Rheumatic Diseases (2021)

Background: Ophthalmological involvement is one of the most feared manifestations of Behçet’s disease [1-6]. Objectives: Our aim was to define the main demographic and clinical features of ophthalmological involvement in a well-defined cohort of patients with Behçet’s disease. Methods: Descriptive study of a cohort of 120 patients diagnosed with Behçet’s disease from January 1, 1980 to December 31, 2019. Finally, following the 2014 International Criteria for Behçet’s Disease (ICBD) ( J Eur Acad Dermatol Venereol 2014; 28:338-47 ) 94 patients were chosen for this study. Results: 50 patients (28 men/22 women; male to female ratio of 1:0.8) had ocular involvement. Mean age at diagnosis was 37.6±11.8 years. Mean ICBD score was 5.8±1.3 points. Neurological involvement was the most frequent manifestation in this group. Genital ulcers were more frequent in the non-ophthalmological involvement group. Systemic clinical domains are shown in Figure 1. The most frequent ocular manifestations were uveitis (n=44, 88.0%), retinal vasculitis (n=5, 10%) and dry eye (n=5, 10%). Likewise, the most frequent type of uveitis was anterior (n=17, 38.6%), followed by posterior uveitis (n=14, 31.8%). 26 (59.1%) of all uveitis were unilateral. Panuveitis was more frequent among patients under 60 years. Similarly, anterior uveitis was predominant in patients older than 70 years. There were no remarkable differences between genders. Main clinical features are shown in Table 1. Table 1. Clinical characteristics of ocular Behçet’s disease. n (% ) Unilateral, n (% ) Bilateral, n (% ) Uveitis 44 (88.0) 26 (59.1) 18 (40.9) Anterior 17 (38.6) 13 (76.5) 4 (23.5) Intermediate 2 (4.5) - 2 (100) Posterior 14 (31.8) 9 (64.3) 5 (35.7) Panuveitis 11 (25.0) 4 (36.4) 7 (73.6) Retinal vasculitis 5 (10.0) - - Dry eye 5 (10.0) - - Cystoid macular edema 4 (8.0) - - Episcleritis 3 (6.0) 3 (100) - Optic neuritis 2 (4.0) - - Conclusion: Ophthalmological involvement in Behçet’s disease was more frequent in men. Uveitis and retinal vasculitis were the most frequent ocular manifestation. No remarkable differences in clinical features were observed between genders. References: [1]Atienza-Mateo B, et al. Arthritis Rheumatol. 2019; 71(12):2081-2089. doi: 10.1002/art.41026 [2]Martín-Varillas JL, et al. Ophthalmology. 2018; 125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020 [3]Atienza-Mateo B, et al. Rheumatology (Oxford). 2018;57(5):856-864. doi: 10.1093/rheumatology/kex480 [4]Vegas-Revenga N, et al. Am J Ophthalmol. 2019;200:85-94. doi: 10.1016/j.ajo.2018.12.019 [5]Calvo-Río V, et al. Clin Exp Rheumatol. 2014;32(4 Suppl 84): S54-7. PMID: 25005576 [6]Santos-Gómez M, et al. Clin Exp Rheumatol. 2016;34(6 Suppl 102): S34-S40. PMID:27054359 Figure 1. Comparison between clinical domains in patients with and without ophthalmological involvement. Disclosure of Interests: Alba Herrero-Morant: None declared, Guillermo Suárez-Amorín: None declared, Rosalía Demetrio-Pablo: None declared, Lara Sanchez-Bilbao: None declared, Carmen Álvarez-Reguera: None declared, David Martínez-López: None declared, Raúl Fernández Ramón: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Lilly, Janssen, and Celgene, M. Cristina Mata-Arnaiz: None declared, Miguel Á. González-Gay Speakers bureau: AbbVie, Pfizer, Roche, Sanofi, Lilly, Celgene and MSD, Grant/research support from: AbbVie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, Sanofi, Lilly and MSD, Grant/research support from: AbbVie, MSD, and Roche